Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
Executive Summary
FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.
You may also be interested in...
Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
Lilly's Olumiant Resubmission Includes Safety Data From US FDA's Sentinel Network
Lilly used Reagan-Udall’s IMEDS to tap Sentinel for data on incidence of venous thromboembolism in patients with rheumatoid arthritis.
Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.